SMT201400156B - Composizione di gel di brimonidina - Google Patents

Composizione di gel di brimonidina

Info

Publication number
SMT201400156B
SMT201400156B SM201400156T SM201400156T SMT201400156B SM T201400156 B SMT201400156 B SM T201400156B SM 201400156 T SM201400156 T SM 201400156T SM 201400156 T SM201400156 T SM 201400156T SM T201400156 B SMT201400156 B SM T201400156B
Authority
SM
San Marino
Prior art keywords
gel composition
brimonidine gel
brimonidine
composition
gel
Prior art date
Application number
SM201400156T
Other languages
English (en)
Italian (it)
Inventor
Jean-Chritophe Buge
Fourcade Karine Nadau
Yril Meunier
Original Assignee
Galderma Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=44789371&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SMT201400156(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from FR1058612A external-priority patent/FR2966366B1/fr
Application filed by Galderma Sa filed Critical Galderma Sa
Publication of SMT201400156B publication Critical patent/SMT201400156B/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/235—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/19—Cosmetics or similar toiletry preparations characterised by the composition containing inorganic ingredients
    • A61K8/29—Titanium; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
    • A61K8/34—Alcohols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
    • A61K8/34—Alcohols
    • A61K8/345—Alcohols containing more than one hydroxy group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
    • A61K8/37—Esters of carboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
    • A61K8/494—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with more than one nitrogen as the only hetero atom
    • A61K8/4946—Imidazoles or their condensed derivatives, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
    • A61K8/81—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds obtained by reactions involving only carbon-to-carbon unsaturated bonds
    • A61K8/8141—Compositions of homopolymers or copolymers of compounds having one or more unsaturated aliphatic radicals, each having only one carbon-to-carbon double bond, and at least one being terminated by only one carboxyl radical, or of salts, anhydrides, esters, amides, imides or nitriles thereof; Compositions of derivatives of such polymers
    • A61K8/8147—Homopolymers or copolymers of acids; Metal or ammonium salts thereof, e.g. crotonic acid, (meth)acrylic acid; Compositions of derivatives of such polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
    • A61K8/84—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds obtained by reactions otherwise than those involving only carbon-carbon unsaturated bonds
    • A61K8/86—Polyethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/16—Emollients or protectives, e.g. against radiation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/08—Anti-ageing preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/40—Chemical, physico-chemical or functional or structural properties of particular ingredients
    • A61K2800/59—Mixtures
    • A61K2800/592—Mixtures of compounds complementing their respective functions
    • A61K2800/5922—At least two compounds being classified in the same subclass of A61K8/18
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/40—Chemical, physico-chemical or functional or structural properties of particular ingredients
    • A61K2800/59—Mixtures
    • A61K2800/594—Mixtures of polymers

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Dermatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Birds (AREA)
  • Inorganic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Emergency Medicine (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Gerontology & Geriatric Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Cosmetics (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Colloid Chemistry (AREA)
SM201400156T 2010-10-21 2014-10-27 Composizione di gel di brimonidina SMT201400156B (it)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US40538810P 2010-10-21 2010-10-21
FR1058612A FR2966366B1 (fr) 2010-10-21 2010-10-21 Composition de gel de brimonidine

Publications (1)

Publication Number Publication Date
SMT201400156B true SMT201400156B (it) 2015-01-15

Family

ID=44789371

Family Applications (1)

Application Number Title Priority Date Filing Date
SM201400156T SMT201400156B (it) 2010-10-21 2014-10-27 Composizione di gel di brimonidina

Country Status (25)

Country Link
US (2) US20130261126A1 (de)
EP (2) EP2444068B2 (de)
JP (2) JP2013540143A (de)
KR (1) KR101506102B1 (de)
CN (1) CN103298451B (de)
AR (1) AR083651A1 (de)
AU (1) AU2011317554B2 (de)
BR (1) BR112013009578B1 (de)
CA (1) CA2814952C (de)
DK (1) DK2444068T4 (de)
ES (1) ES2498217T5 (de)
HR (1) HRP20140811T1 (de)
IL (2) IL225760A (de)
MX (1) MX354697B (de)
NO (1) NO2444068T3 (de)
NZ (1) NZ610121A (de)
PL (1) PL2444068T5 (de)
PT (1) PT2444068E (de)
RS (1) RS53531B1 (de)
RU (1) RU2571277C2 (de)
SG (1) SG189896A1 (de)
SI (1) SI2444068T1 (de)
SM (1) SMT201400156B (de)
WO (1) WO2012052479A2 (de)
ZA (2) ZA201302859B (de)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104666239A (zh) * 2013-11-27 2015-06-03 杭州赛利药物研究所有限公司 酒石酸溴莫尼定凝胶及其制备方法
CN103919717A (zh) * 2014-04-15 2014-07-16 天津中医药大学 一种酒石酸溴莫尼定眼用凝胶制剂及其制备方法和用途
WO2016052947A1 (ko) * 2014-09-29 2016-04-07 (주)네오팜 건성 치료용 산성 외용제 조성물
IL304011A (en) * 2016-08-31 2023-08-01 Taro Pharma Ind Topical formulations of phenoldopam for the treatment of skin problems
EP3651767A1 (de) * 2017-07-14 2020-05-20 Galderma Research & Development Verfahren und zusammensetzungen zur reduzierung von nebenwirkungen bei chemotherapeutischen behandlungen
CN108126186B (zh) * 2017-12-28 2021-10-29 未名生物医药有限公司 一种含神经生长因子的水凝胶及其制备方法
TW202045165A (zh) * 2019-02-20 2020-12-16 美商Ａｉ治療公司 局部雷帕黴素調配物以及其於治療臉部血管纖維瘤和其他皮膚疾病中的用途
CA3131049A1 (en) 2019-03-08 2020-09-17 Taro Pharmaceutical Industries Ltd. Stable topical compositions of fenoldopam
WO2020222192A1 (en) * 2019-05-01 2020-11-05 Clexio Biosciences Ltd. Methods of treating pruritus
CN116159018A (zh) * 2023-03-01 2023-05-26 中国药科大学 一种新型外用溴莫尼定凝胶剂

Family Cites Families (105)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3278447A (en) 1963-12-02 1966-10-11 Cloro Bac Products Inc Process for stabilizing chlorine dioxide solution
US3560501A (en) 1966-09-15 1971-02-02 Ciba Geigy Corp Process for making dihydroquinazolines
BG16042A3 (bg) 1968-11-12 1972-05-20 Nans Ott Метод за получаване на нови 2(1н)-хиназолинони
US3594380A (en) 1969-02-18 1971-07-20 American Home Prod Isoquinolin-1(2h)-ones
BE766039A (fr) 1971-04-21 1971-09-16 Labofina Sa Nouveaux polymeres contenant des unites de pyrazole et procede de preparation de ces polymeres.
US3740442A (en) 1972-01-14 1973-06-19 Sandoz Ag 2-isopropylaminobenzophenones in treating inflammation
US4029792A (en) 1972-02-29 1977-06-14 Pfizer Inc. (2-Imidazolin-2-ylamino) substituted -quinoxalines and -quinazolines as antihypertensive agents
BE795970A (fr) 1972-02-29 1973-08-27 Pfizer Nouveaux derives de quinoleine, quinoxaline et quinazoline er composition pharmaceutiques les contenant
US4164570A (en) 1973-09-24 1979-08-14 David Clough Stabilized aqueous catecholamine solutions
US4201211A (en) 1977-07-12 1980-05-06 Alza Corporation Therapeutic system for administering clonidine transdermally
US4285967A (en) 1978-06-30 1981-08-25 Estee Lauder Inc. Cosmetic preparation for reducing redness of blemishes
US4256763A (en) 1978-09-19 1981-03-17 Mchugh John E Treatment of herpes simplex infections and acne
US5166331A (en) 1983-10-10 1992-11-24 Fidia, S.P.A. Hyaluronics acid fractions, methods for the preparation thereof, and pharmaceutical compositions containing same
IL92351A (en) 1988-11-29 1994-02-27 Allergan Inc Irvine Optimal aqueous solutions containing stabilized chlorine acid and inorganic salt
FR2648709A1 (fr) 1989-06-23 1990-12-28 Boehringer Ingelheim France Nouvelle utilisation de derives de 1-phenyl-2-aminoethanol en tant que moyens cicatrisants
US5112822A (en) 1989-10-12 1992-05-12 Allergan, Inc. (2-imidazolin-2-ylamino) quinoxaline derivatives and methods for using same
US5198442A (en) 1989-10-12 1993-03-30 Allergan, Inc. (2-imidazolin-2-ylamino) quinoxaline derivatives and methods for using same
US5326763A (en) 1989-10-12 1994-07-05 Allergan, Inc. Methods for using (2-imidazolin-2-ylamino) quinoxaline derivatives
US5204347A (en) 1989-10-12 1993-04-20 Allergan, Inc. Methods for using (2-imidazolin-2-ylamino) tetrahydroquinoxalines
US5077292A (en) 1989-10-12 1991-12-31 Allergan, Inc. (2-imidazolin-2-ylamino) tetrahydroquinoxalines and methods for using same
US5021416A (en) 1989-10-31 1991-06-04 Allergan, Inc. Method for using (2-imidazolin-2-ylamino) quinoxalines to reduce or maintain intraocular pressure
US5237072A (en) 1990-02-06 1993-08-17 Allergan, Inc. Method for producing amino-2-imidazoline derivatives
US5130441A (en) 1990-02-06 1992-07-14 Allergan, Inc. Method for producing amino-2-imidazoline derivatives
US5721237A (en) 1991-05-10 1998-02-24 Rhone-Poulenc Rorer Pharmaceuticals Inc. Protein tyrosine kinase aryl and heteroaryl quinazoline compounds having selective inhibition of HER-2 autophosphorylation properties
US5736165A (en) 1993-05-25 1998-04-07 Allergan In-the-eye use of chlorine dioxide-containing compositions
EP1285657A3 (de) 1993-10-13 2003-08-20 Allergan, Inc. Verfahren zur Verwendung von (2-imidazolin-2-yl-amino) Quinoxalinderivaten
US6323204B1 (en) 1993-10-13 2001-11-27 Allergan Methods for using (2-imidazolin-2-ylamino) quinoxaline derivatives
US6117871A (en) 1993-12-17 2000-09-12 The Procter & Gamble Company 6-(2-imidazolinylamino)quinoxaline compounds useful as alpha-2 adrenoceptor agonists
WO1996013267A2 (en) 1994-10-27 1996-05-09 Allergan Combinations of prostaglandins and brimonidine or derivatives thereof for the treatment of glaucoma
US6294563B1 (en) 1994-10-27 2001-09-25 Allergan Sales, Inc. Combinations of prostaglandins and brimonidine or derivatives thereof
US5696133A (en) 1994-12-22 1997-12-09 Ligand Pharmaceuticals Incorporated Steroid receptor modulator compounds and methods
WO1996025163A1 (en) 1995-02-14 1996-08-22 Board Of Supervisors Or Louisiana State Universityof Agricultural And Mechanical College Through Itsmedical Center Treatment of herpes simplex viruses
US6194415B1 (en) 1995-06-28 2001-02-27 Allergan Sales, Inc. Method of using (2-imidazolin-2-ylamino) quinoxoalines in treating neural injury
US5720962A (en) 1995-10-04 1998-02-24 Au Pharmaceuticals, Inc. Analgesic lotion for hemorrhoids and method of making such lotion
US6441047B2 (en) 1995-11-17 2002-08-27 Alcon Manufacturing Ltd.. Combination therapy for treating glaucoma
US5863560A (en) 1996-09-11 1999-01-26 Virotex Corporation Compositions and methods for topical application of therapeutic agents
US5753637A (en) 1996-10-09 1998-05-19 Ideal Ideas, Inc. Method of treating acne conditions
US5916574A (en) 1996-10-09 1999-06-29 Ideal Ideas, Inc. Method of treating natural poison skin conditions
EP0969790A2 (de) 1997-02-21 2000-01-12 Beiersdorf Aktiengesellschaft Zubereitungen für die behandlung von rosacea
US6007846A (en) 1997-05-16 1999-12-28 Townley Jewelry, Inc. Scented body gel having particulate matter in the form of glitter with predetermined shapes
US6159944A (en) 1998-02-27 2000-12-12 Synchroneuron, Llc Method for treating painful conditions of the anal region and compositions therefor
CN1235559C (zh) 1998-03-11 2006-01-11 株式会社创研 皮肤水分保持能力的改善剂
US6432934B1 (en) 1998-08-06 2002-08-13 Advanced Vision Research Methods and compositions for topical treatment of eye surface inflammation and related dry eye disease
US20030087962A1 (en) 1998-10-20 2003-05-08 Omeros Corporation Arthroscopic irrigation solution and method for peripheral vasoconstriction and inhibition of pain and inflammation
US20020197300A1 (en) 1999-02-22 2002-12-26 Schultz Clyde L. Drug delivery system for anti-glaucomatous medication
WO2000076502A1 (en) 1999-06-11 2000-12-21 The Ohio State University Research Foundation Methods and compositions for treating raynaud's phenomenon and scleroderma
US6147102A (en) 1999-10-26 2000-11-14 Curatek Pharmaceuticals Holding, Inc. Clonidine preparations
US20030077301A1 (en) 1999-12-16 2003-04-24 Maibach Howard I. Topical pharmaceutical composition for the treatment of inflammatory dermatoses
US6294553B1 (en) 2000-02-15 2001-09-25 Allergan Sales, Inc. Method for treating ocular pain
US6284765B1 (en) 2000-04-27 2001-09-04 The University Of North Texas Health Science Center At Fort Worth (+) naloxone and epinephrine combination therapy
US6444681B1 (en) 2000-06-09 2002-09-03 The Ohio State University Research Foundation Methods and compositions for treating Raynaud's Phenomenon and scleroderma
US6468989B1 (en) 2000-07-13 2002-10-22 Dow Pharmaceutical Sciences Gel compositions containing metronidazole
US6387383B1 (en) 2000-08-03 2002-05-14 Dow Pharmaceutical Sciences Topical low-viscosity gel composition
US7211267B2 (en) 2001-04-05 2007-05-01 Collagenex Pharmaceuticals, Inc. Methods of treating acne
US20020198209A1 (en) 2001-05-03 2002-12-26 Allergan Sales Inc. Compositions having enhanced pharmacokinetic characteristics
TNSN02063A1 (en) 2001-07-07 2005-12-23 Egyptian Natural Oil Co Natoil The medical effect of jojoba oil
US7115724B2 (en) 2001-08-22 2006-10-03 Wyeth Murine genomic polynucleotide sequence encoding a G-protein coupled receptor and methods of use therefor
US6680062B2 (en) 2001-10-05 2004-01-20 Color Access, Inc. Anti-irritating rosacea treatment
US7001615B1 (en) 2001-12-07 2006-02-21 Alcon, Inc. Sustained release ophthalmic, otic and nasal suspension
AUPS167602A0 (en) 2002-04-12 2002-05-16 F.H. Faulding & Co. Limited An improved modified release preparation
US7345065B2 (en) 2002-05-21 2008-03-18 Allergan, Inc. Methods and compositions for alleviating pain
US20040266776A1 (en) 2003-06-25 2004-12-30 Gil Daniel W. Methods of preventing and reducing the severity of stress-associated conditions
US20040092482A1 (en) 2002-11-07 2004-05-13 Gupta Shyam K. Hydroxy acids based delivery systems for skin resurfacing and anti-aging compositions
US20040156873A1 (en) 2003-02-10 2004-08-12 Gupta Shyam K. Topically Bioavailable Acne and Rosacea Treatment Compositions
US20040220259A1 (en) 2003-04-04 2004-11-04 Yu Ruey J. Topical treatment of dermatological disorders associated with reactive or dilated blood vessels
EP1622554A4 (de) 2003-05-15 2008-01-02 Bioform Medical Inc Zusammensetzungen mit einer kombination aus einem pharmazeutischen mittel oder einem kosmetischen mittel und einem eine oxy-gruppe tragenden aromatischen aldehyd
US8410102B2 (en) 2003-05-27 2013-04-02 Galderma Laboratories Inc. Methods and compositions for treating or preventing erythema
US7439241B2 (en) 2003-05-27 2008-10-21 Galderma Laboratories, Inc. Compounds, formulations, and methods for treating or preventing rosacea
US20050059664A1 (en) 2003-09-12 2005-03-17 Allergan, Inc. Novel methods for identifying improved, non-sedating alpha-2 agonists
US20050020600A1 (en) 2003-07-23 2005-01-27 Scherer Warren J. Methods of treating cutaneous flushing using selective alpha-2-adrenergic receptor agonists
US20050059744A1 (en) 2003-09-12 2005-03-17 Allergan, Inc. Methods and compositions for the treatment of pain and other alpha 2 adrenergic-mediated conditions
US7285544B2 (en) 2003-11-18 2007-10-23 Bernstein Eric F Use of nitroxides in treating skin disease
US7812049B2 (en) 2004-01-22 2010-10-12 Vicept Therapeutics, Inc. Method and therapeutic/cosmetic topical compositions for the treatment of rosacea and skin erythema using α1-adrenoceptor agonists
US20050196418A1 (en) 2004-03-04 2005-09-08 Yu Ruey J. Bioavailability and improved delivery of alkaline pharmaceutical drugs
PL1761266T3 (pl) * 2004-05-25 2013-09-30 Galderma Pharma Sa Związki, preparaty i sposoby leczenia lub zapobiegania procesom zapalnym skóry
US20070003622A1 (en) 2004-12-16 2007-01-04 Sovereign Pharmaceuticals, Ltd. Diphenhydramine containing dosage form
US7288263B2 (en) 2004-09-13 2007-10-30 Evera Laboratories, Llc Compositions and methods for treatment of skin discoloration
US8158161B2 (en) 2005-01-12 2012-04-17 S.U.L.V.E. Ltd. Methods and pharmaceutical compositions useful for treating psoriasis
WO2006084031A1 (en) 2005-02-01 2006-08-10 Icagen, Inc. Imines as ion channel modulators
US20070082070A1 (en) 2005-10-11 2007-04-12 Stookey Evangeline L Treating skin disorders
CA2644311C (en) 2006-03-01 2012-07-10 Tristrata, Inc. Composition and method for topical treatment of tar-responsive dermatological disorders
US20070258935A1 (en) 2006-05-08 2007-11-08 Mcentire Edward Enns Water dispersible films for delivery of active agents to the epidermis
EP2020995A2 (de) 2006-05-09 2009-02-11 Mallinckrodt Inc. Feste darreichungsformen mit modifizierter freisetzung nullter ordnung
CA2672973C (en) 2006-12-21 2016-03-08 Novagali Pharma Sa Process for manufacturing ophthalmic oil-in-water emulsions
WO2008144399A1 (en) 2007-05-18 2008-11-27 Bausch & Lomb Incorporated COMPLEXES COMPRISING α2-ADRENERGIC RECEPTOR AGONISTS AND COMPOSITIONS
RU2350342C1 (ru) * 2007-07-04 2009-03-27 Общество с ограниченной ответственностью "Корпорация "СпектрАкустика" Способ изготовления геля на основе водного экстракта из пантов
US20090060852A1 (en) 2007-07-27 2009-03-05 Jack Dejovin Compounds, Formulations and Methods for Reducing Skin Wrinkles, Creasing and Sagging
US20090061020A1 (en) † 2007-08-31 2009-03-05 Theobald Klaus P Brimonidine Compositions for Treating Erythema
HUE042931T2 (hu) 2007-11-16 2019-07-29 Aclaris Therapeutics Inc Kompozíciók és eljárások purpura kezelésére
NZ586302A (en) * 2007-12-21 2013-03-28 Galderma Lab Inc Pre-surgical treatment using brimonidine applied topically to reduce bleeding or bruising
EP2090307A1 (de) 2008-02-15 2009-08-19 Bone Therapeutics Pharmazeutische Zusammensetzung zur Behandlung oder Verhinderung von Knochengelenkserkrankungen
US20090306025A1 (en) 2008-05-30 2009-12-10 Fairfield Clinical Trials, Llc Method and composition for skin inflammation and discoloration
WO2009158646A1 (en) 2008-06-27 2009-12-30 Elixir Pharmaceuticals, Inc. Therapeutic compunds and related methods of use
US20100029662A1 (en) 2008-08-01 2010-02-04 Alpha Synergy Development, Inc. Vasoconstriction compositions and methods of use
WO2010027349A1 (en) 2008-09-03 2010-03-11 Transdermal Innovations Inc. Multipurpose hydrogel compositions and products
FR2936149B1 (fr) † 2008-09-23 2013-01-04 Francois Fauran Utilisation de l'alverine dans le traitement des affections cutanees
US20100196291A1 (en) 2009-01-30 2010-08-05 Laurence Halimi Personal care sunscreen compositions having reduced eye irritation
JP5052558B2 (ja) * 2009-04-03 2012-10-17 ロート製薬株式会社 ゲル軟膏
AU2010252935C1 (en) 2009-05-29 2015-05-28 Galderma Research & Development Injectable combination of adrenergic receptor agonists with fillers, for decreasing skin reactions due to injection
BR112012009891A2 (pt) 2009-10-26 2015-09-29 Galderma Pharma Sa métodos para tratar eritema agudo e para prevenir o eritema agudo e uma inflamação secundária em um humano em necessidade do mesmo
US8394800B2 (en) 2009-11-19 2013-03-12 Galderma Laboratories, L.P. Method for treating psoriasis
KR20150058551A (ko) 2010-03-26 2015-05-28 갈데르마 리써어치 앤드 디벨로프먼트 모세혈관 확장증의 안전하고 유효한 치료를 위한 개선된 방법 및 조성물
DK2552449T3 (en) 2010-03-26 2017-06-19 Galderma Res & Dev COMPOSITIONS INCLUDING BRIMONIDINE FOR TREATMENT OF ERYTHEM
US8053427B1 (en) 2010-10-21 2011-11-08 Galderma R&D SNC Brimonidine gel composition
US20120101104A1 (en) 2010-10-21 2012-04-26 Galderma S.A. Topical gel compositions and methods of use

Also Published As

Publication number Publication date
JP2013540143A (ja) 2013-10-31
RS53531B1 (en) 2015-02-27
EP2444068B1 (de) 2014-07-23
EP2629757A2 (de) 2013-08-28
NO2444068T3 (de) 2014-12-20
SI2444068T1 (sl) 2014-11-28
DK2444068T4 (en) 2018-03-05
HRP20140811T1 (hr) 2014-12-19
MX2013004473A (es) 2013-10-30
JP6185536B2 (ja) 2017-08-23
IL225760A0 (en) 2013-06-27
WO2012052479A3 (en) 2012-07-05
CN103298451B (zh) 2016-04-20
JP2016014072A (ja) 2016-01-28
IL251543B (en) 2022-01-01
EP2444068B2 (de) 2017-12-06
KR101506102B1 (ko) 2015-03-25
PL2444068T3 (pl) 2014-11-28
US20160331715A1 (en) 2016-11-17
PL2444068T5 (pl) 2018-04-30
ZA201402758B (en) 2017-05-31
BR112013009578B1 (pt) 2020-10-20
PT2444068E (pt) 2014-09-22
IL225760A (en) 2017-07-31
ES2498217T5 (es) 2018-03-19
RU2013123042A (ru) 2014-11-27
WO2012052479A2 (en) 2012-04-26
RU2571277C2 (ru) 2015-12-20
NZ610121A (en) 2015-04-24
CA2814952A1 (en) 2012-04-26
DK2444068T3 (da) 2014-09-15
SG189896A1 (en) 2013-06-28
US10201517B2 (en) 2019-02-12
CN103298451A (zh) 2013-09-11
MX354697B (es) 2018-03-15
EP2444068A1 (de) 2012-04-25
US20130261126A1 (en) 2013-10-03
IL251543A0 (en) 2017-05-29
BR112013009578A2 (pt) 2016-07-12
CA2814952C (en) 2016-05-10
AU2011317554A1 (en) 2013-05-09
AU2011317554B2 (en) 2015-04-30
ES2498217T3 (es) 2014-09-24
ZA201302859B (en) 2014-07-25
AR083651A1 (es) 2013-03-13
KR20130101549A (ko) 2013-09-13

Similar Documents

Publication Publication Date Title
SMT201700008B (it) Composizione farmaceutica
SMT201500271B (it) Inibitori di neprilisina
SMT201500054B (it) 2-Anilinobenzimidazolo-6-carbossammidi come agentianti-infiammattori
BR112012031667A2 (pt) composição
BR112013011472A2 (pt) Composição de gel
DK2640893T4 (da) Sammensætninger
BR112013016037A2 (pt) composição em gel.
BR112012032683A2 (pt) composição
DK3246018T3 (da) Farmaceutisk sammensætning
BR112013014989A2 (pt) completamento de poço
SMT201400156B (it) Composizione di gel di brimonidina
IT1400743B1 (it) Composizioni polimeriche
DK3095817T3 (da) Mikrogelsammensætninger
EE201300005A (et) Ravimkoostis
FR2955770B1 (fr) Composition cosmetique.
BR112012032980A2 (pt) composição
BR112013014612A2 (pt) composições moc
FR2958537B1 (fr) Composition dentaire
FR2957252B1 (fr) Composition cosmetique
ITTO20110268A1 (it) Composizione di maquillage.
BR112012029461A2 (pt) composição farmacêutica contendo solifenacina
SMT201400194B (it) Complesso di flurano
BR112013014821A2 (pt) géis espalháveis
DK2652241T3 (da) Brøndkomplettering
BR112013000109A2 (pt) composições